Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,686,947
  • Shares Outstanding, K 96,031
  • Annual Sales, $ 129,160 K
  • Annual Income, $ -36,240 K
  • 60-Month Beta 2.13
  • Price/Sales 16.01
  • Price/Cash Flow N/A
  • Price/Book 5.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.49
  • Number of Estimates 6
  • High Estimate -0.14
  • Low Estimate -0.67
  • Prior Year 0.79
  • Growth Rate Est. (year over year) -162.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.02 +55.06%
on 01/03/20
30.41 -18.32%
on 01/27/20
+6.56 (+35.89%)
since 12/27/19
3-Month
14.51 +71.14%
on 11/13/19
30.41 -18.32%
on 01/27/20
+9.15 (+58.32%)
since 10/28/19
52-Week
14.24 +74.44%
on 10/18/19
30.41 -18.32%
on 01/27/20
+3.47 (+16.24%)
since 01/28/19

Most Recent Stories

More News
Denali Therapeutics Announces Pricing of Public Offering of Common Stock

Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 7,826,087 shares of its common stock at a price to the public of $23.00 per share. All of the...

JPM : 134.43 (+1.82%)
DNLI : 24.84 (-11.22%)
AVEO Posts Data on Ficlatuzumab From Pancreatic Cancer Study

AVEO releases results from a phase Ib study on ficlatuzumab in combination with nab-paclitaxel and gemcitabine for treating advanced pancreatic cancer. Shares inch up.

LLY : 139.26 (+0.69%)
AVEO : 0.53 (-12.06%)
PDLI : 3.23 (unch)
DNLI : 24.84 (-11.22%)
Denali Therapeutics Announces Proposed Offering of Common Stock

Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering of $150 million of shares of its common stock. In...

JPM : 134.43 (+1.82%)
DNLI : 24.84 (-11.22%)
Axsome (AXSM) Completes Patient Randomization in TRD Study

Axsome (AXSM) closes patient randomization in the late-stage study of AXS-05 for addressing patients with treatment resistant depression.

PDLI : 3.23 (unch)
EPZM : 21.81 (+2.11%)
AXSM : 87.60 (+0.72%)
DNLI : 24.84 (-11.22%)
Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance

The FDA receives Evoke Pharma's (EVOK) refiling of new drug application for its pipeline candidate Gimoti, which is being developed to treat diabetic gastroparesis.

PDLI : 3.23 (unch)
EPZM : 21.81 (+2.11%)
EVOK : 1.48 (+3.50%)
DNLI : 24.84 (-11.22%)
Novavax Rises on Fast Track Designation to Influenza Vaccine

The FDA bestows a Fast Track Designation on Novavax's (NVAX) influenza vaccine candidate NanoFlu for adults aged 65 years and older. Shares rally.

SNY : 48.27 (+1.05%)
EXAS : 90.71 (+3.16%)
NVAX : 7.17 (-15.65%)
DNLI : 24.84 (-11.22%)
Perrigo (PRGO) Rises on Stellar Q419 Preliminary Results

Perrigo (PRGO) announces better-than-expected preliminary results for fourth-quarter 2019 as well as the full year. Shares gain.

PRGO : 59.52 (+1.47%)
EXAS : 90.71 (+3.16%)
DNLI : 24.84 (-11.22%)
PETQ : 30.30 (+0.07%)
Denali Therapeutics Sees Hammer Chart Pattern: Time to Buy?

Denali Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

DNLI : 24.84 (-11.22%)
Emergent (EBS) Posts Preliminary '19 Results, Gives 2020 View

Emergent (EBS) narrows revenue view for 2019 and expects a consistent rise in Narcan nasal spray sales during 2020.

SNY : 48.27 (+1.05%)
GSK : 46.80 (+0.69%)
EBS : 55.75 (+4.13%)
DNLI : 24.84 (-11.22%)
Flagship Unveils Newest Pioneering Platform: Ring Therapeutics

Flagship Pioneering, a unique life sciences innovation enterprise, today announced the launch of Ring Therapeutics, an early-stage biotechnology company developing first-in-class gene therapies using a...

AXLA : 5.21 (-0.57%)
DNLI : 24.84 (-11.22%)
EVLO : 7.06 (+4.13%)
KLDO : 8.31 (-9.67%)
MRNA : 22.36 (-1.67%)
RUBY : 8.07 (+1.25%)
MCRB : 3.22 (unch)
SYRS : 7.26 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Trade DNLI with:

Business Summary

Denali Therapeutics Inc. is a biotechnology company. It focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and others. Denali Therapeutics Inc. is based in SOUTH SAN FRANCISCO,...

See More

Key Turning Points

2nd Resistance Point 29.31
1st Resistance Point 27.08
Last Price 24.84
1st Support Level 23.68
2nd Support Level 22.51

See More

52-Week High 30.41
Last Price 24.84
Fibonacci 61.8% 24.23
Fibonacci 50% 22.33
Fibonacci 38.2% 20.42
52-Week Low 14.24

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar